[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100387552":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":51,"collaborators":18,"id":53,"slug":18,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":18,"enrollmentInfo":62,"targetDuration":18,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":18,"overallStatus":33,"whyStopped":18,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nice","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Cohort","All patients included will have to be taken blood samples",[12],"Other: Blood sample",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"Blood sample","Serum samples will be sent for centralised analyses in Nice.\n\nOn these samples, different analysis will be performed :\n\n* anti-PLA2R1 and anti-THSD7A antibodies\n* anti-PLA2R1 and anti-THSD7A epitopes\n* HLA typing",[9],null,[20],{"name":21,"affiliation":22,"role":23},"Barbara Seitz-polski","Hopital de l'Archet laboratoire immunology, 151 route de sain-Antoine de Ginestière 06200 Nice","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Barbara SEITZ-POLSKI, MD","CONTACT","+33 4 92 03 55 02","seitz-polski.b@chu-nice.fr",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"CHU de Nice, Hôpital de l'Archet","RECRUITING","Nice","Alpes Maritime","06200","France",{"type":39,"coordinates":40},"Point",[41,42],7.26608,43.70313,{"lat":42,"lon":41},[45,48,50],{"name":46,"role":27,"phone":47,"phoneExt":18,"email":29},"Barbara Seitz-Polski","+33492035502",{"name":49,"role":27,"phone":18,"phoneExt":18,"email":18},"Barbara SEITZ-POLSKI, PhD",{"name":46,"role":23,"phone":18,"phoneExt":18,"email":18},{"type":52,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100387552",false,"NCT04326218","Immunopathological Analysis in a French National Cohort of Membranous Nephropathy","Immunopathological Analysis in a French National Cohort of Membranous Nephropathy (IHMN)","IHMN","Inclusion Criteria:\n\n* Age 18 years or more\n* Biopsy on a native kidney consistent with MN and\u002For positivity for serum anti-PLA2R1 and\u002For anti-THSD7A antibodies\n* Signed informed consent\n\nExclusion Criteria:\n\n* Diagnosis error based on the kidney biopsy staining or on serology analyses for the positivity for anti-PLA2R1 and\u002For anti-THSD7A\n* Patients unable to give an informed consent\n* Patients withdrawing an informed consent","ALL","18 Years",{"count":63,"type":64},400,"ESTIMATED","INTERVENTIONAL",[67],"NA","National cohort of all cases of membranous nephropathy (MN) during a 1 year period in France, based on a pathological and\u002For serological diagnostic, collecting the data on:\n\n* incidence of MN\n* prevalence of anti-PLA2R1 and anti-THSD7A\n* clinical outcome one year after diagnosis or after relapse (complete remission, partial remission or persistent nephrotic syndrome)\n* environmental risk factors for the onset of MN\n* HLA markers\n* patient care status in France",[70],"Membranous Nephropathy","2026-06-15",{"date":73,"type":74},"2026-06-16","ACTUAL",{"date":76,"type":74},"2020-07-04",{"date":78,"type":64},"2031-12-03",{"name":5,"class":6},1]